Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among...
from NDTV News - Topstories https://ift.tt/3HTxies
from NDTV News - Topstories https://ift.tt/3HTxies
Comments
Post a Comment